Where does Nina Kjellson work?

Nina Kjellson is General Partner at Canaan Partners and Founder at Annum Health and Founder at Cidara Therapeutics and Founder at Eiger Biopharmaceuticals.

What check size does Nina Kjellson write?

Nina Kjellson typically writes checks of $250K – $20M.

Nina Kjellson

InvestorFounder

General Partner at Canaan Partners · Board director at Annum Health · Board director at Cidara Therapeutics · Board director at Eiger Biopharmaceuticals

Menlo Park, California

Writes $250K – $20M checks · typically $10M

FoundedAnnum Health Cidara Therapeutics Eiger Biopharmaceuticals Lycera TYRA Biosciences

About

Nina Kjellson brings a Nordic perspective to biotech, focusing on therapeutics for serious underserved conditions like addiction and neurological disease, and champions women in healthcare and tech via WoVen podcast

Invests in

BiotechConsumerDeep TechEnterprise SoftwareFintechHardware

Board director at Annum Health

Intro paths

→

In turn, Nina can intro founders to Annum Health's investors below.

Annum Health's investors · 5

.406 VenturesBoston · $1M – $4M checks ARC Angel FundNew York · $50K – $250K checks AXA Venture PartnersNew York Canaan PartnersStamford · $500K – $20M checks · since 2016 Elevate Innovation PartnersNew York

Co-founders at Annum Health

Lauren WolfeExecutive Officer

Michael LaskoffExecutive Officer, Director, Promoter

Mark WillenbringExecutive Officer

Board director at Cidara Therapeutics

Intro paths

→

In turn, Nina can intro founders to Cidara Therapeutics's investors below.

Cidara Therapeutics's investors · 7

5AM VenturesBoston · $100K – $4M checks · since 2015 Aisling CapitalNew York Canaan PartnersStamford · $500K – $20M checks · since 2015 Frazier Life SciencesPalo Alto · since 2015 RA CapitalBoston Venrock Healthcare Capital PartnersNew York Vivo CapitalPalo Alto · $10M – $50M checks

Co-founders at Cidara Therapeutics

Jeffrey SteinExecutive Officer, Director

Kevin JudiceDirector

Kevin ForrestExecutive Officer

Dirk ThyeExecutive Officer

Ken BartizalExecutive Officer

Paul DaruwalaExecutive Officer

Board director at Eiger Biopharmaceuticals

Intro paths

→

In turn, Nina can intro founders to Eiger Biopharmaceuticals's investors below.

Eiger Biopharmaceuticals's investors · 3

Canaan PartnersStamford · $500K – $20M checks · since 2011 Pfizer Venture Investments$5M – $20M checks · since 2015 Vivo CapitalPalo Alto · $10M – $50M checks · since 2016

Co-founders at Eiger Biopharmaceuticals

Jeffrey GlennDirector

David CoryExecutive Officer, Director

Experience

Pelican Advisors LLC - Family Office and AdvisoryPartnercurrent2024 — present
Canaan PartnersGeneral Partnercurrent2015 — presentMenlo Park, CA
Actio Biosciences, Inc.Board Membercurrent2023 — present
ProxygenBoard Membercurrent2023 — presentVienna, Austria
Rondo TherapeuticsBoard Membercurrent2022 — present
Trishula Therapeutics, Inc.Board Membercurrent2020 — present
Tizona Therapeutics, Inc.Board Membercurrent2016 — presentSan Francisco Bay Area
Biotechnology Innovation OrganizationBoard Membercurrent2024 — present
Foundation for the National Institutes of HealthBoard Membercurrent2024 — present
The Aspen InstituteHealth Innovators' Fellowcurrent2018 — present
All RaiseMembercurrent2021 — present
Life Science Cares Bay AreaCo-Chair Board of Trustees - nonprofitcurrent2020 — present
Girl EffectBoard Member - nonprofitcurrent2019 — present
WoVen: platform amplifying the ambitions and achievements of women who ventureFoundercurrent2014 — present
Sardona TherapeuticsBoard Member2021 — 2025
Blueprint Health LLCMentor2012 — 2025New York City Metropolitan Area
Blueprint Health LLCMentor2011 — 2015
Tyra BiosciencesBoard Member2020 — 2025
Panacea Acquisition Corp. IIBoard Member2021 — 2023
Essential Access HealthChairwoman - nonprofit2016 — 2023San Francisco Bay Area

Education

Stanford UniversityBA, Human Biology1992 — 1997
Phillips Exeter Academy

Skills & more

Enterprise Software1Strategy26Leadership8Oncology3Business Strategy15Lifesciences36Venture Capital84Private Equity12Biotechnology43Technology Transfer4Investments23M&A experience7

+12 more

Corporate DevelopmentMedical DevicesPharmaceutical IndustryEntrepreneurshipGo-to-market StrategyVenture FinancingAngel InvestingGrowth CapitalStart-upsDrug DiscoveryBusiness DevelopmentDeal Sourcing

From Nina's professional profile.

Deals · 7

TYRA BiosciencesBoard seat

via Canaan Partners · filed Feb 2024 · $200M raise

Vitruvian NetworksBoard seat

via Canaan Partners · filed Apr 2018 · $33.5M raise

Annum HealthBoard seat

via Canaan Partners · filed Oct 2016 · $2.5M raise

WellTok, Inc.Board seat

via Canaan Partners · filed Dec 2015 · $45M raise

LyceraBoard seat

via Canaan Partners · filed Jun 2015

Eiger BiopharmaceuticalsBoard seat

via Canaan Partners · filed Mar 2015 · $14.6M raise

Cidara TherapeuticsBoard seat

via Canaan Partners · filed Feb 2015 · $42M raise

Attribution from SEC filings, press coverage, and firm rosters.

Colleagues at Canaan Partners

Antonio Lepore

Investor at Canaan Partners

Brendan Dickinson

General Partner at Canaan Partners

Brent Ahrens

General Partner at Canaan Partners

Colleen Cuffaro

Partner at Canaan Partners

Dana Malman Warren

Investor at Canaan Partners

Deepak Kamra

General Partner at Canaan Partners

Evan Teiger

Investor at Canaan Partners

Felipe Ossio

Investor at Canaan Partners

Frequently asked questions

Where does Nina Kjellson work?: Nina Kjellson is General Partner at Canaan Partners and Founder at Annum Health and Founder at Cidara Therapeutics and Founder at Eiger Biopharmaceuticals.
What does Nina Kjellson invest in?: Nina Kjellson invests in Biotech, Consumer, Deep Tech, Enterprise Software, Fintech, Hardware.
What check size does Nina Kjellson write?: Nina Kjellson typically writes checks of $250K – $20M.
What companies did Nina Kjellson found?: Nina Kjellson founded Annum Health, Cidara Therapeutics, Eiger Biopharmaceuticals, Lycera, TYRA Biosciences.